PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF REDUCING SEBUM PRODUCTION USING SAME
The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production.
1 . A pharmaceutical composition comprising 15-HETrE and a retinoid analogue.
2 . The pharmaceutical composition of claim 1 wherein the retinoid analogue is adapalene.
3 . A topically deliverable pharmaceutical composition comprising a therapeutically effective amount of 15-HETrE and a retinoid analogue.
4 . The topically deliverable composition of claim 3 wherein the retinoid analogue is adapalene.
5 . The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene.
6 . The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 0.01 wt. % to about 20 wt. % of 15-HETrE.
7 . The pharmaceutical composition of claim 1 , wherein the composition is a cream.
8 . A method of treating or inhibiting development of acne in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 .
9 . The method of claim 8 , wherein the step of administering comprises applying the pharmaceutical composition to an area of skin of the subject afflicted with acne lesions.
10 . The method of claim 8 , wherein the acne is associated with Propionibacterium acnes.
11 . The method of claim 8 , wherein the pharmaceutical composition is administered to the subject once a day, twice a day, or three times a day.
12 . The method of claim 8 , wherein the pharmaceutical composition is a cream.
13 . The method of claim 8 , wherein the pharmaceutical composition comprises about 0.1 wt. % to about 20 wt. % of 15-HETrE.
14 . The method of claim 8 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene.